Limits...
Medicaid spending and utilization for central nervous system drugs.

Baugh DK, Pine PL, Blackwell S, Ciborowski G - Health Care Financ Rev (2004)

Bottom Line: The analysis examines cost variation by census region, State, Medicaid basis of eligibility, and therapeutic use of drugs.In 1998, the highest expenditures were for central nervous system (CNS) drugs and for anti-psychotics compared to three other groups of CNS drugs (anti-anxiety agents, anti-depressants, and hypnotics).There were major variations among SMRF States and their respective regions.

View Article: PubMed Central - PubMed

Affiliation: Centers for Medicare & Medicaid Services (CMS), Baltimore, MD 21244-1850, USA. dbaugh@cms.hhs.gov

ABSTRACT
Prior research has shown that prescription drug spending grew substantially during the decade of the 1990s. This analysis uses 1996 to 1998 State Medicaid Research File (SMRF) fee-for-service (FFS) data for 29 participating States to provide insight into the factors driving this growth. The analysis examines cost variation by census region, State, Medicaid basis of eligibility, and therapeutic use of drugs. In 1998, the highest expenditures were for central nervous system (CNS) drugs and for anti-psychotics compared to three other groups of CNS drugs (anti-anxiety agents, anti-depressants, and hypnotics). By eligibility group, expenditures were typically highest for disabled enrollees. There were major variations among SMRF States and their respective regions.

Show MeSH

Related in: MedlinePlus

Medicaid Number of Prescriptions Per Recipient for Central Nervous System (CNS) Drugs for 29 SMRF States, by Basis of Eligibility and CNS Drug Group: 1998In the 29 SMRF States, Disabled Enrollees Were Among the Highest Users of CNS Drugs?Prescriptions per recipient for the disabled were higher for each CNS drug group than they were for any of the other basis of eligibility groups, with one exception. The exception was that the aged used more anti-depressants per recipient than the disabled.Usage of anti-psychotics by the disabled, 10.4 prescriptions per recipient, was substantially higher than usage of these drugs by other basis of eligibility groups—6.8 for the aged, 5.1 for children and 2.6 for adults.With the exception of children, anti-anxiety drugs were used more frequently, on a per recipient basis, than hypnotics. Per recipient use of both anti-anxiety and hypnotic drugs was much lower than anti-depressants and anti-psychotics for all basis of eligibility groups except adults.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4194875&req=5

f8-hcfr-26-1-057: Medicaid Number of Prescriptions Per Recipient for Central Nervous System (CNS) Drugs for 29 SMRF States, by Basis of Eligibility and CNS Drug Group: 1998In the 29 SMRF States, Disabled Enrollees Were Among the Highest Users of CNS Drugs?Prescriptions per recipient for the disabled were higher for each CNS drug group than they were for any of the other basis of eligibility groups, with one exception. The exception was that the aged used more anti-depressants per recipient than the disabled.Usage of anti-psychotics by the disabled, 10.4 prescriptions per recipient, was substantially higher than usage of these drugs by other basis of eligibility groups—6.8 for the aged, 5.1 for children and 2.6 for adults.With the exception of children, anti-anxiety drugs were used more frequently, on a per recipient basis, than hypnotics. Per recipient use of both anti-anxiety and hypnotic drugs was much lower than anti-depressants and anti-psychotics for all basis of eligibility groups except adults.

Mentions: Payment per recipient for anti-psychotics for the disabled ($1,188) was nearly three times the amount for the aged ($443) and children ($438) and nearly five times the amount for adults ($215). This finding is the result of at least two major factors: payment and utilization. Payment per prescription for anti-psychotics for the disabled was very high (Figure 7). Also, utilization of anti-psychotics by the disabled was also very high (Figure 8).


Medicaid spending and utilization for central nervous system drugs.

Baugh DK, Pine PL, Blackwell S, Ciborowski G - Health Care Financ Rev (2004)

Medicaid Number of Prescriptions Per Recipient for Central Nervous System (CNS) Drugs for 29 SMRF States, by Basis of Eligibility and CNS Drug Group: 1998In the 29 SMRF States, Disabled Enrollees Were Among the Highest Users of CNS Drugs?Prescriptions per recipient for the disabled were higher for each CNS drug group than they were for any of the other basis of eligibility groups, with one exception. The exception was that the aged used more anti-depressants per recipient than the disabled.Usage of anti-psychotics by the disabled, 10.4 prescriptions per recipient, was substantially higher than usage of these drugs by other basis of eligibility groups—6.8 for the aged, 5.1 for children and 2.6 for adults.With the exception of children, anti-anxiety drugs were used more frequently, on a per recipient basis, than hypnotics. Per recipient use of both anti-anxiety and hypnotic drugs was much lower than anti-depressants and anti-psychotics for all basis of eligibility groups except adults.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4194875&req=5

f8-hcfr-26-1-057: Medicaid Number of Prescriptions Per Recipient for Central Nervous System (CNS) Drugs for 29 SMRF States, by Basis of Eligibility and CNS Drug Group: 1998In the 29 SMRF States, Disabled Enrollees Were Among the Highest Users of CNS Drugs?Prescriptions per recipient for the disabled were higher for each CNS drug group than they were for any of the other basis of eligibility groups, with one exception. The exception was that the aged used more anti-depressants per recipient than the disabled.Usage of anti-psychotics by the disabled, 10.4 prescriptions per recipient, was substantially higher than usage of these drugs by other basis of eligibility groups—6.8 for the aged, 5.1 for children and 2.6 for adults.With the exception of children, anti-anxiety drugs were used more frequently, on a per recipient basis, than hypnotics. Per recipient use of both anti-anxiety and hypnotic drugs was much lower than anti-depressants and anti-psychotics for all basis of eligibility groups except adults.
Mentions: Payment per recipient for anti-psychotics for the disabled ($1,188) was nearly three times the amount for the aged ($443) and children ($438) and nearly five times the amount for adults ($215). This finding is the result of at least two major factors: payment and utilization. Payment per prescription for anti-psychotics for the disabled was very high (Figure 7). Also, utilization of anti-psychotics by the disabled was also very high (Figure 8).

Bottom Line: The analysis examines cost variation by census region, State, Medicaid basis of eligibility, and therapeutic use of drugs.In 1998, the highest expenditures were for central nervous system (CNS) drugs and for anti-psychotics compared to three other groups of CNS drugs (anti-anxiety agents, anti-depressants, and hypnotics).There were major variations among SMRF States and their respective regions.

View Article: PubMed Central - PubMed

Affiliation: Centers for Medicare & Medicaid Services (CMS), Baltimore, MD 21244-1850, USA. dbaugh@cms.hhs.gov

ABSTRACT
Prior research has shown that prescription drug spending grew substantially during the decade of the 1990s. This analysis uses 1996 to 1998 State Medicaid Research File (SMRF) fee-for-service (FFS) data for 29 participating States to provide insight into the factors driving this growth. The analysis examines cost variation by census region, State, Medicaid basis of eligibility, and therapeutic use of drugs. In 1998, the highest expenditures were for central nervous system (CNS) drugs and for anti-psychotics compared to three other groups of CNS drugs (anti-anxiety agents, anti-depressants, and hypnotics). By eligibility group, expenditures were typically highest for disabled enrollees. There were major variations among SMRF States and their respective regions.

Show MeSH
Related in: MedlinePlus